0 6 Second second JJ 7 16 messenger messenger NN 17 30 up-regulation up-regulation NN 31 33 of of IN 34 42 androgen androgen NN 43 51 receptor receptor NN 52 56 gene gene NN 57 70 transcription transcription NN 71 73 is be VBZ 74 80 absent absent JJ 81 83 in in IN 84 92 androgen androgen NN 93 104 insensitive insensitive JJ 105 110 human human JJ 111 120 prostatic prostatic JJ 121 130 carcinoma carcinoma NN 131 135 cell cell NN 136 141 lines line NNS 141 142 , , , 143 147 PC-3 PC-3 NNP 148 151 and and CC 152 158 DU-145 DU-145 NNP 158 159 . . . 161 162 A a DT 163 174 theoretical theoretical JJ 175 182 pathway pathway NN 183 185 of of IN 186 201 transcriptional transcriptional JJ 202 212 regulation regulation NN 213 215 of of IN 216 219 the the DT 220 228 androgen androgen NN 229 237 receptor receptor NN 238 239 ( ( ( 239 241 AR AR NNP 241 242 ) ) ) 243 247 gene gene NN 248 250 is be VBZ 251 254 via via IN 255 256 a a DT 257 261 cAMP camp NN 262 270 response response NN 271 278 element element NN 279 280 ( ( ( 280 283 CRE CRE NNP 283 284 ) ) ) 285 292 present present JJ 293 295 in in IN 296 299 its its PRP$ 300 308 promoter promoter NN 309 315 region region NN 316 317 ( ( ( 317 321 -508 -508 CD 322 324 to to TO 325 329 -501 -501 CD 329 330 ) ) ) 330 331 . . . 332 337 After after IN 338 340 20 20 CD 341 342 h h NN 343 345 of of IN 346 357 stimulation stimulation NN 358 362 with with IN 363 375 8-bromo-cAMP 8-bromo-cAMP NNP 375 376 , , , 377 379 AR AR NNP 380 384 mRNA mRNA NNP 385 388 was be VBD 389 400 upregulated upregulate VBN 401 403 in in IN 404 409 LNCaP LNCaP NNP 410 413 but but CC 414 417 not not RB 418 420 in in IN 421 427 either either CC 428 432 PC-3 PC-3 NNP 433 435 or or CC 436 442 DU-145 DU-145 NNP 443 447 cell cell NN 448 453 lines line NNS 453 454 . . . 455 457 We we PRP 458 462 have have VBP 463 475 demonstrated demonstrate VBN 476 480 that that IN 481 484 the the DT 485 490 level level NN 491 493 of of IN 494 497 CRE CRE NNP 498 505 binding binding NN 506 513 protein protein NN 514 515 ( ( ( 515 519 CREB CREB NNP 519 520 ) ) ) 521 524 was be VBD 525 528 the the DT 529 533 same same JJ 534 536 in in IN 537 540 all all DT 541 545 cell cell NN 546 551 lines line NNS 552 555 and and CC 556 560 that that IN 561 564 the the DT 565 573 putative putative JJ 574 580 AR-CRE ar-cre NN 581 586 forms form NNS 587 595 specific specific JJ 596 599 and and CC 600 610 compatible compatible JJ 611 618 protein protein NN 619 631 interactions interaction NNS 632 636 with with IN 637 641 CREB CREB NNP 641 642 . . . 643 646 The the DT 647 654 ability ability NN 655 657 to to TO 658 666 regulate regulate VB 667 669 AR ar NN 670 674 gene gene NN 675 688 transcription transcription NN 689 692 via via IN 693 696 the the DT 697 703 second second JJ 704 713 messenger messenger NN 714 721 pathway pathway NN 722 724 is be VBZ 725 729 lost lose VBN 730 732 in in IN 733 736 the the DT 737 741 PC-3 PC-3 NNP 742 745 and and CC 746 752 DU-145 DU-145 NNP 753 757 cell cell NN 758 763 lines line NNS 763 764 . . . 765 769 This this DT 770 773 may may MD 774 776 be be VB 777 779 an an DT 780 789 important important JJ 790 797 primary primary JJ 798 807 mechanism mechanism NN 808 810 of of IN 811 819 androgen androgen NN 820 833 insensitivity insensitivity NN 834 836 in in IN 837 845 prostate prostate NN 846 852 cancer cancer NN 852 853 . . .